News

TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis


2 May 2010
by Working Group

New research to speed TB drugs to those who need it most

New York and Bangalore, India, May 3, 2010 The TB Alliance and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB), including drug-resistant strains of the disease. One in five patients with TB are resistant to at least one of today’s standard first-line TB drugs according to the World Health Organization.

AstraZeneca has a well-established TB drug discovery program and is a crucial participant in the Critical Path to New TB Regimens. Together, our research promises to bring important advances to TB patients in need.

Under the agreement, the TB Alliance and AstraZeneca will both contribute promising TB drug discovery projects into a joint portfolio that will be co-developed by both parties. Sharing resources and creating a seamless path to clinical-stage development will improve the efficiency of both organizations’ research programs. By focusing on novel compound classes, the drug candidates identified by the collaboration are likely to be effective against both drug-resistant and drug-sensitive tuberculosis. The financial terms were not disclosed.

The initial set of projects contributed by the TB Alliance results from its ongoing collaboration with several world-leading researchers at the University of Pennsylvania, Rutgers University and New York Medical College. AstraZeneca’s projects come from its TB research center in Bangalore, India. The joint portfolio will be resourced by a core group of scientists at the center with expertise and funding provided by both organizations.

Promising compounds identified in this collaboration will also be tested in combination with other therapies as part of the Critical Path to TB Regimens, a cross-sector initiative intended to speed TB drug regimens to patients who need them.

“Collaboration is absolutely vital to developing the tools needed to truly revolutionize the way TB is treated and overcome the global TB epidemic,” said Mel Spigelman, M.D., President and CEO, TB Alliance. “AstraZeneca has a well-established TB drug discovery program and is a crucial participant in the Critical Path to New TB Regimens. Together, our research promises to bring important advances to TB patients in need.”

Les Hughes, AstraZeneca’s Vice President of Infection Discovery said: “AstraZeneca is building a leading franchise in the treatment of infectious diseases, both through our own in-house research as well as through collaborations. This collaboration is part of the global partnership that will be needed to conquer the TB epidemic. We are excited to be working with the TB Alliance to help move forward the drug discovery program and quickly speed promising candidates into clinical development.”

> click here to read more

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...